Medivir Strengthens its Management Team

Medivir Strengthens its Management Team

Huddinge, Sweden - Medivir AB (OMX: MVIR), an emerging research-based
specialty pharmaceutical company focused on infectious diseases, today
announces several new appointments to its executive management team.

Ron Long, CEO of Medivir commented, “These appointments will support
Medivir as it continues to progress its research and commercial
capabilities and will provide the company with a stronger operational
and strategic management team to develop Medivir's existing R&D projects
and marketed products”.

Dr Maris Hartmanis has been appointed to Medivir's management team as
deputy CEO and COO (Chief Operating Officer). In parallel to this
appointment Maris Hartmanis will continue to work as CEO of Biophausia,
the specialty pharmaceutical company which recently was acquired by
Medivir. Maris Hartmanis has extensive experience of the pharmaceutical
industry, most notably holding senior positions at Gambro, Amersham and
Pharmacia.

Professor Bertil Samuelsson has been appointed CSA (Chief Scientific
Advisor). Bertil Samuelsson previously held the position of CSO (Chief
Scientific Officer) and will leave the operational management team to
focus his efforts on the strategic development of Medivir's R&D,
including new project opportunities.

Medivir also names Dr Charlotte Edenius as Executive VP Research &
Development. In her new role she will assume the operational
responsibilities for Medivir's Research and Development. Charlotte
Edenius currently holds the position as VP Research & Development
projects at Medivir.

In order to strengthen Medivir's capabilities in clinical development Dr
Jens D. Kristensen has been recruited as Executive VP Clinical to head
the clinical unit at Medivir. Prior to joining Medivir Jens Kristensen
most recently served as Vice President Clinical Development at Karo Bio
and also has experience working at AstraZeneca within clinical
development.

For more information about Medivir, please contact:

Medivir (www.medivir.com (http://www.medivir.com/)):
Rein Piir, CFO & VP Investor Relations                Mobile:
+46 708 537 292

About MedivirMedivir is an emerging research-based specialty
pharmaceutical company focused on the development of high-value
treatments for infectious diseases. Medivir has world class expertise in
polymerase and protease drug targets and drug development which has
resulted in a strong infectious disease R&D portfolio. The Company's key
pipeline asset is TMC435, a novel protease inhibitor is in phase 3
clinical development for hepatitis C and is partnered with Tibotec
Pharmaceuticals. In June 2011, Medivir acquired the specialty
pharmaceutical company BioPhausia to ensure timely commercialization of
TMC435 in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®
was launched on the US market in February 2011. Xerese®/Xerclear®, which
has been approved in both the US and Europe is partnered with
GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in
North America, Canada and Mexico have recently been sold to Meda AB.
Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company's website:
www.medivir.com (http://www.medivir.com/).